Medifast (NYSE:MED) Director Acquires $51,948.00 in Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai purchased 4,329 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The stock was bought at an average cost of $12.00 per share, for a total transaction of $51,948.00. Following the completion of the purchase, the director directly owned 665,517 shares in the company, valued at $7,986,204. This represents a 0.65% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Parsa Kiai also recently made the following trade(s):

• On Wednesday, August 26th, Parsa Kiai acquired 43,150 shares of Medifast stock. The stock was purchased at an average price of $12.26 per share, for a total transaction of $529,019.00.
• On Thursday, August 20th, Parsa Kiai acquired 43,150 shares of Medifast stock. The shares were purchased at an average price of $11.60 per share, with a total value of $500,540.00.
• On Wednesday, August 19th, Parsa Kiai acquired 29,337 shares of Medifast stock. The shares were purchased at an average price of $11.66 per share, with a total value of $342,069.42.

Medifast Price Performance

Shares of Medifast stock opened at $12.17 on Friday. The business has a 50 day simple moving average of $11.00 and a two-hundred day simple moving average of $11.10. Medifast Inc has a 12 month low of $9.22 and a 12 month high of $14.67. The stock has a market capitalization of $136.06 million, a P/E ratio of -5.22 and a beta of 0.65.

Medifast (NYSE:MED) last issued its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.The firm had revenue of $76.38 million for the quarter, compared to analyst estimates of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. As a group, research analysts anticipate that Medifast Inc will post -1.04 EPS for the current fiscal year.

Institutional Trading of Medifast

Hedge funds and other institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Medifast by 30.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock worth $8,297,000 after acquiring an additional 181,618 shares during the period. Bank of America Corp DE grew its holdings in shares of Medifast by 14.2% in the third quarter. Bank of America Corp DE now owns 452,543 shares of the specialty retailer’s stock valued at $6,186,000 after purchasing an additional 56,174 shares during the period. BlackRock Inc. purchased a new stake in shares of Medifast in the second quarter valued at about $3,920,000. Dimensional Fund Advisors LP increased its position in Medifast by 10.9% during the first quarter. Dimensional Fund Advisors LP now owns 361,762 shares of the specialty retailer’s stock worth $3,686,000 after purchasing an additional 35,522 shares during the last quarter. Finally, Lido Advisors LLC acquired a new stake in Medifast during the third quarter worth about $4,521,000. 95.51% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Zacks Research downgraded shares of Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $12.00.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight?loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight?management solutions.